Page last updated: 2024-10-24

carmustine and Cognition Disorders

carmustine has been researched along with Cognition Disorders in 4 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

Excerpt	Relevance	Reference
"Patients with brain metastases had improvements in their cognitive trajectory, especially memory and executive function, after treatment with resection plus CW."	2.78	Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. ( Booth-Jones, M; Brem, S; Ewend, MG; Jain, S; Meyers, CA; Palmer, G, 2013)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brem, S	1
Meyers, CA	1
Palmer, G	1
Booth-Jones, M	1
Jain, S	1
Ewend, MG	1
Corn, BW	1
Wang, M	1
Fox, S	1
Michalski, J	1
Purdy, J	1
Simpson, J	1
Kresl, J	1
Curran, WJ	1
Diaz, A	1
Mehta, M	1
Movsas, B	1
Harder, H	1
Holtel, H	1
Bromberg, JE	1
Poortmans, P	1
Haaxma-Reiche, H	1
Kluin-Nelemans, HC	1
Menten, J	1
van den Bent, MJ	1
Alvarnas, JC	1
Negrin, RS	1
Horning, SJ	1
Hu, WW	1
Long, GD	1
Schriber, JR	1
Stockerl-Goldstein, K	1
Tierney, K	1
Wong, R	1
Blume, KG	1
Chao, NJ	1

Clinical Trials (4)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer[NCT00525590]	Phase 2	69 participants (Actual)	Interventional	2007-12-12	Completed
Prospective and Retrospective Memory Perception Assessment in Central/Non-central Nervous System Cancers[NCT03975959]		420 participants (Anticipated)	Interventional	2019-05-10	Recruiting
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	1998-09-30	Completed
Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)[NCT00003061]	Phase 2	50 participants (Anticipated)	Interventional	1997-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With Neurologic Death

Neurologic Death was defined as death due to progression of neurologic disease. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)

Intervention	percentage of participants (Number)
GLIADEL	1.9

Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12

NF was assessed as the performance of 3 neurocognitive domains:memory(MD),executive function(EFD), fine motor coordination(FMCD). For each domain, z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted and education-adjusted normative distribution of scores from an unimpaired population.Individual z-scores from related tests were averaged to determine overall z-score.If a z-score average decreased from baseline by greater than or equal to(>=)3 standard deviations(SD)in tests' normative age-adjusted distribution on 2 consecutive visits or decreased by >=3 SD on last follow-up visit, participant were considered to have significant deterioration in their NF at time of the first decrease in z-score.Deterioration in NF:demonstrated deterioration for at least two of the three neurocognitive domains based on these changes from screening.Rate of deterioration in NF was measured as estimated percentage of participants using Kaplan-Meier method. (NCT00525590)
Timeframe: Month 12

Intervention	percentage of participants (Number)
GLIADEL	2.8

Time to Neurocognitive Deterioration

The time to neurocognitive deterioration was defined as the number of days between the date of study treatment and the date of neurocognitive deterioration based on NF assessment. This was assessed using Kaplan Meier method. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)

Intervention	months (Number)
GLIADEL	NA

Correlation of Tumor Recurrence (Local, Distant or Overall) With NF Domain Scores

The correlation between recurrence (local, distant or overall) & NF was assessed by presenting change in NF domain scores (memory domain [MD], executive function domain [EFD], fine motor coordination domain [FMCD]) after tumor recurrence (Visits X, X+1, X+2, and X+3) compared to before tumor recurrence (Visit X-1). Here 'Visit X' refers to visit at which participants had tumor recurrence, Visit X-1 refers to visit immediately before the recurrence and X+1, X+2, X+3 refers to subsequent first, second & third visit after the recurrence.NF domain z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted &education-adjusted normative distribution of scores from an unimpaired population. Individual z-scores from related tests were averaged to determine overall z-score for each of NF domains. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)

Intervention	z-score (Mean)
	Local Recurrence: MD at Visit (X-1)	Local Recurrence: MD Change at Visit (X-1)	Local Recurrence: MD Change at Visit (X+1)	Local Recurrence: MD Change at Visit (X+2)	Local Recurrence: MD Change at Visit (X+3)	Local Recurrence: EFD at Visit (X-1)	Local Recurrence: EFD Change at Visit (X-1)	Local Recurrence: EFD Change at Visit (X+1)	Local Recurrence: EFD Change at Visit (X+2)	Local Recurrence: EFD Change at Visit (X+3)	Local Recurrence: FMCD at Visit (X-1)	Local Recurrence: FMCD Change at Visit (X-1)	Local Recurrence: FMCD Change at Visit (X+1)	Local Recurrence: FMCD Change at Visit (X+2)	Local Recurrence: FMCD Change at Visit (X+3)	Distant Recurrence: MD at Visit (X-1)	Distant Recurrence: MD Change at Visit (X-1)	Distant Recurrence: MD Change at Visit (X+1)	Distant Recurrence: MD Change at Visit (X+2)	Distant Recurrence: MD Change at Visit (X+3)	Distant Recurrence: EFD at Visit (X-1)	Distant Recurrence: EFD Change at Visit (X-1)	Distant Recurrence: EFD Change at Visit (X+1)	Distant Recurrence: EFD Change at Visit (X+2)	Distant Recurrence: EFD Change at Visit (X+3)	Distant Recurrence: FMCD at Visit (X-1)	Distant Recurrence: FMCD Change at Visit (X-1)	Distant Recurrence: FMCD Change at Visit (X+1)	Distant Recurrence: FMCD Change at Visit (X+2)	Distant Recurrence: FMCD Change at Visit (X+3)	Overall Recurrence: MD at Visit (X-1)	Overall Recurrence: MD Change at Visit (X-1)	Overall Recurrence: MD Change at Visit (X+1)	Overall Recurrence: MD Change at Visit (X+2)	Overall Recurrence: MD Change at Visit (X+3)	Overall Recurrence: EFD at Visit (X-1)	Overall Recurrence: EFD Change at Visit (X-1)	Overall Recurrence: EFD Change at Visit (X+1)	Overall Recurrence: EFD Change at Visit (X+2)	Overall Recurrence: EFD Change at Visit (X+3)	Overall Recurrence: FMCD at Visit (X-1)	Overall Recurrence: FMCD Change at Visit (X-1)	Overall Recurrence: FMCD Change at Visit (X+1)	Overall Recurrence: FMCD Change at Visit (X+2)	Overall Recurrence: FMCD Change at Visit (X+3)
GLIADEL	-0.9	-1.1	0.7	0.1	-0.8	-0.4	-0.5	0.2	-0.0	-1.1	-1.5	0.4	0.5	-0.4	0.3	-1.0	0.2	-0.2	-0.2	-0.7	-0.2	-0.2	-0.5	-0.8	-0.8	-1.2	-0.1	-0.4	-1.1	-0.1	-0.9	-0.1	-0.1	-0.2	-0.7	-0.1	-0.3	-0.5	-0.6	-0.8	-1.2	0.0	-0.3	-0.9	-0.1

Number of Participants With Neurocognitive Domains Preserved at Month 12

Preservation of NF was defined as a decrease of less than or equal to (<=) 1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 12

Intervention	Participants (Count of Participants)
	Domains preserved=3	Domains preserved=2	Domains preserved=1	Domains preserved=0
GLIADEL	9	5	0	0

Number of Participants With Neurocognitive Domains Preserved at Month 2

Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 2

Intervention	Participants (Count of Participants)
	Domains preserved=3	Domains preserved=2	Domains preserved=1	Domains preserved=0
GLIADEL	26	12	4	3

Number of Participants With Neurocognitive Domains Preserved at Month 4

Intervention	Participants (Count of Participants)
	Domains preserved=3	Domains preserved=2	Domains preserved=1	Domains preserved=0
GLIADEL	24	9	2	1

Number of Participants With Neurocognitive Domains Preserved at Month 6

Intervention	Participants (Count of Participants)
	Domains preserved=3	Domains preserved=2	Domains preserved=1	Domains preserved=0
GLIADEL	17	5	2	0

Number of Participants With Neurocognitive Domains Preserved at Month 9

Intervention	Participants (Count of Participants)
	Domains preserved=3	Domains preserved=2	Domains preserved=1	Domains preserved=0
GLIADEL	14	6	0	0

Percentage of Participants With Brain Tumor Recurrence (Local Recurrence, Distant Recurrence and Overall Recurrence)

(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)

Intervention	percentage of participants (Number)
	Local Recurrence	Distant Recurrence	Overall Recurrence
GLIADEL	28.0	48.0	62.0

Percentage of Participants With Neurocognitive Decline in NF by Severity (Memory Domain, Executive Function Domain, and Fine Motor Coordination Domain)

Neurocognitive decline was defined as any decrease in NF scores less than (<) 0 SD from baseline. Here, in category titles EFD represents Executive Function Domain and FMCD represents Fine Motor Coordination Domain. (NCT00525590)
Timeframe: Months 2, 4, 6, 9 and 12

Intervention	percentage of participants (Number)
	Month 2: Memory Domain, decline <0 to -1 SD	Month 2: Memory Domain, decline <-1 to -2 SD	Month 2: Memory Domain, decline <-2 to -3 SD	Month 2: Memory Domain, decline <-3 to -4 SD	Month 2: Memory Domain, decline <-4 to -5 SD	Month 2: Memory Domain, decline <-5 SD	Month 2: EFD, decline <0 to -1 SD	Month 2: EFD, decline <-1 to -2 SD	Month 2: EFD, decline <-2 to -3 SD	Month 2: EFD, decline <-3 to -4 SD	Month 2: EFD, decline <-4 to -5 SD	Month 2: EFD, decline <-5 SD	Month 2: FMCD, decline <0 to -1 SD	Month 2: FMCD, decline <-1 to -2 SD	Month 2: FMCD, decline <-2 to -3 SD	Month 2: FMCD, decline <-3 to -4 SD	Month 2: FMCD, decline <-4 to -5 SD	Month 2: FMCD, decline <-5 SD	Month 4: Memory Domain, decline <0 to -1 SD	Month 4: Memory Domain, decline <-1 to -2 SD	Month 4: Memory Domain, decline <-2 to -3 SD	Month 4: Memory Domain, decline <-3 to -4 SD	Month 4: Memory Domain, decline <-4 to -5 SD	Month 4: Memory Domain, decline <-5 SD	Month 4: EFD, decline <0 to -1 SD	Month 4: EFD, decline <-1 to -2 SD	Month 4: EFD, decline <-2 to -3 SD	Month 4: EFD, decline <-3 to -4 SD	Month 4: EFD, decline <-4 to -5 SD	Month 4: EFD, decline <-5 SD	Month 4: FMCD, decline <0 to -1 SD	Month 4: FMCD, decline <-1 to -2 SD	Month 4: FMCD, decline <-2 to -3 SD	Month 4: FMCD, decline <-3 to -4 SD	Month 4: FMCD, decline <-4 to -5 SD	Month 4: FMCD, decline <-5 SD	Month 6: Memory Domain, decline <0 to -1 SD	Month 6: Memory Domain, decline <-1 to -2 SD	Month 6: Memory Domain, decline <-2 to -3 SD	Month 6: Memory Domain, decline <-3 to -4 SD	Month 6: Memory Domain, decline <-4 to -5 SD	Month 6: Memory Domain, decline <-5 SD	Month 6: EFD, decline <0 to -1 SD	Month 6: EFD, decline <-1 to -2 SD	Month 6: EFD, decline <-2 to -3 SD	Month 6: EFD, decline <-3 to -4 SD	Month 6: EFD, decline <-4 to -5 SD	Month 6: EFD, decline <-5 SD	Month 6: FMCD, decline <0 to -1 SD	Month 6: FMCD, decline <-1 to -2 SD	Month 6: FMCD, decline <-2 to -3 SD	Month 6: FMCD, decline <-3 to -4 SD	Month 6: FMCD, decline <-4 to -5 SD	Month 6: FMCD, decline <-5 SD	Month 9: Memory Domain, decline <0 to -1 SD	Month 9: Memory Domain, decline <-1 to -2 SD	Month 9: Memory Domain, decline <-2 to -3 SD	Month 9: Memory Domain, decline <-3 to -4 SD	Month 9: Memory Domain, decline <-4 to -5 SD	Month 9: Memory Domain, decline <-5 SD	Month 9: EFD, decline <0 to -1 SD	Month 9: EFD, decline <-1 to -2 SD	Month 9: EFD, decline <-2 to -3 SD	Month 9: EFD, decline <-3 to -4 SD	Month 9: EFD, decline <-4 to -5 SD	Month 9: EFD, decline <-5 SD	Month 9: FMCD, decline <0 to -1 SD	Month 9: FMCD, decline <-1 to -2 SD	Month 9: FMCD, decline <-2 to -3 SD	Month 9: FMCD, decline <-3 to -4 SD	Month 9: FMCD, decline <-4 to -5 SD	Month 9: FMCD, decline <-5 SD	Month 12: Memory Domain, decline <0 to -1 SD	Month 12: Memory Domain, decline <-1 to -2 SD	Month 12: Memory Domain, decline <-2 to -3 SD	Month 12: Memory Domain, decline <-3 to -4 SD	Month 12: Memory Domain, decline <-4 to -5 SD	Month 12: Memory Domain, decline <-5 SD	Month 12: EFD, decline <0 to -1 SD	Month 12: EFD, decline <-1 to -2 SD	Month 12: EFD, decline <-2 to -3 SD	Month 12: EFD, decline <-3 to -4 SD	Month 12: EFD, decline <-4 to -5 SD	Month 12: EFD, decline <-5 SD	Month 12: FMCD, decline <0 to -1 SD	Month 12: FMCD, decline <-1 to -2 SD	Month 12: FMCD, decline <-2 to -3 SD	Month 12: FMCD, decline <-3 to -4 SD	Month 12: FMCD, decline <-4 to -5 SD	Month 12: FMCD, decline <-5 SD
GLIADEL	27.3	15.9	4.5	0	0	0	37.8	8.1	0	0	0	0	23.8	7.1	2.4	2.4	0	0	19.4	8.3	0	0	2.8	2.8	29.0	0	0	0	0	0	17.1	11.4	0	2.9	0	0	12.5	0	4.2	0	0	0	18.2	4.5	0	0	0	0	12.5	20.8	0	0	0	0	25.0	5.0	0	0	0	0	36.8	5.3	0	0	0	0	20.0	10.0	5.0	0	0	0	14.3	7.1	0	0	0	0	33.3	0	0	0	0	0	7.1	14.3	0	0	0	0

Time to Recurrence (Local, Distant and Overall)

(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)

Intervention	months (Median)
	Time to Local Recurrence	Time to Distant Recurrence	Time to Overall Recurrence
GLIADEL	NA	8.5	6.1

Trials

2 trials available for carmustine and Cognition Disorders

Article	Year
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer, 2013, Nov-01, Volume: 119, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2013
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer, 2013, Nov-01, Volume: 119, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2013
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer, 2013, Nov-01, Volume: 119, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2013
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer, 2013, Nov-01, Volume: 119, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2013
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. Journal of neuro-oncology, 2009, Volume: 95, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2009

Other Studies

2 other studies available for carmustine and Cognition Disorders

Article	Year
Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology, 2004, Feb-24, Volume: 62, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Carmustine; Case-Control Stud	2004
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:3A Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carm	2000